secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001437749-26-008949
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin reports FY2025 results; MIRACLE trial shows 40% blinded CRc rate in first 30 R/R AML patients
--------------------------------------------------------------------------------

- FY2025 R&D expense $15.9M (down from $17.7M), G&A $9.2M; cash $8.9M at year-end; $8.3M raised in Q1 2026; cash runway into Q3 2026.
- MIRACLE trial (Phase 2B/3) Annamycin + cytarabine in R/R AML: blinded CRc 40% in first 30 subjects; interim unblinding for 45 patients expected mid-2026.
- Pipeline progress: WP1066 Phase 1 pediatric brain tumor trial shows safety and immune response; Annamycin GBM collaboration and pancreatic cancer study initiated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/0001437749-26-008949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/mbrx20260317_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-008949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer